Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941811 | 0.91 | ALDH1A1 (0.45) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4938300 | 0.87 | MAPT (0.46) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4944569 | 0.86 | ALDH1A1 (0.43) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4946807 | 0.80 | MAPT (0.32) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL1544681 | 0.79 | ALDH1A1 (0.49) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4941967 | 0.78 | MEN1 (0.47) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4947623 | 0.76 | TSHR (0.46) | MAPTALDH1A1TSHRKMT2APKM | |
| SCHEMBL4946020 | 0.76 | KMT2A (0.48) | MAPTALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4947019 | 0.74 | TSHR (0.47) | MAPTALDH1A1TSHRKMT2APKM | |
| SCHEMBL4940633 | 0.72 | TSHR (0.51) | MAPTALDH1A1TSHRKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | MAPT 780/4885ALDH1A1 3875/4885TSHR 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.